Clinical Trials Browser

Interventional × Neoplasm Metastasis × bosutinib × Clear all

NCT03854903 2025-02-06

WI231696: Bosutinib, Palbocicilib and Fulvestrant for HR+HER2- Advanced Breast Cancer Refractory to a CDK4/6 Inhibitor

Phase 1 Completed

Breast Neoplasms, Neoplasm Metastasis

NCT00319254 2013-01-31

Study Evaluating SKI-606 (Bosutinib) In Subjects With Breast Cancer

Phase 2 Completed

75 enrolled 13 charts

Breast Neoplasms, Neoplasm Metastasis